High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
Authors:
Open Access
- 29 April 2026
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (7) , 6184-6193
Abstract
Aims: Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective: To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care or endocrinology clinics. Materials and Methods: 798 participants recruited from outpatient clinics were risk‐stratified by NIS2+ into low‐risk, intermediate‐risk or having at‐risk MASH (NIS2+ score < 0.46, ≥ 0.46 and < 0.68 or ≥ 0.68, respectively). Presence of steatosis (CAP ≥ 288 dB/m) and clinically significant liver fibrosis (VCTE‐ ≥ 8.0 kPa) was established by transient elastography (FibroScan). Results: At‐risk MASH affected 29% of individuals with both obesity and T2D compared to 3% of those without either condition ( p < 0.001). People with at‐risk MASH, compared to those at low‐risk, more often had steatosis (81% vs. 40%), clinically significant fibrosis (42% vs. 5%), AST or ALT ≥ 40 IU/L, hepatic insulin resistance (by HOMA‐IR) and adipose tissue insulin resistance (by adipo‐IR) (all p < 0.001). NIS2+ strongly correlated with diagnosis of at‐risk MASH by FAST ( r = 0.67; p < 0.001), as well as CK‐18, ALT and AST and liver fibrosis by VCTE‐LSM (all p < 0.001). Conclusion: The prevalence of at‐risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics. Their progression to cirrhosis may be prevented with early risk‐stratification and timely intervention.Keywords
Funding Information
- National Institutes of Health (DK‐120331)
This publication has 45 references indexed in Scilit:
- Is FIB-4 the right tool for screening for liver fibrosis?Annals of Hepatology, 2025
- Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomicsAtherosclerosis, 2024
- Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screenObesity, 2024
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severityActa Diabetologica, 2024
- Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular CarcinomaClinical Gastroenterology and Hepatology, 2024
- Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologistsEndocrinología, Diabetes y Nutrición, 2024
- Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-AnalysisClinical Gastroenterology and Hepatology, 2022
- Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2022
- American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical SettingsEndocrine Practice, 2022
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017